Back to top

Novo Nordisk downgraded to Neutral from Buy at UBS

UBS downgraded Novo Nordisk (NVO) to Neutral from Buy with a price target of DKK 340, down from DKK 600. The firm sees “challenging times” for the ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NOV Inc. (NOV)

Novo Nordisk A/S (NVO)